What topics does this cannabis study cover?

This study covers research on: Appetite, Endocannabinoid, Inflammation.

Targeting liver cannabinoid receptors could revolutionize obesity treatment

Q: Where was this research published?

Published in Obesity reviews : an official journal of the International Association for the Study of Obesity on May 14, 2026.

Is Hepatic Cannabinoid 1 Receptor a Key Driver of Obesity? Implications of the Weight-Reducing Efficacy of the Hepatotropic Inverse Agonist TM38837.

Obesity reviews : an official journal of the International Association for the Study of Obesity • May 14, 2026 • Moderately Relevant

🤖

AI Summary

This research paper challenges our current understanding of how cannabinoid 1 (CB1) receptor activation contributes to obesity, specifically focusing on the liver's role. The study highlights the potential of TM38837, a new drug that targets CB1 receptors exclusively in the liver while avoiding the brain, which showed significant weight loss in obese rodents with minimal side effects. This finding is significant because most previous attempts to develop CB1 receptor inhibitors for weight loss have failed due to unwanted psychiatric and neurological side effects when these drugs also affected the brain.

The researchers propose a novel mechanism explaining why hepatic CB1 receptor activity drives obesity. Rather than simple metabolic dysregulation, they suggest that upregulated CB1 receptors in liver cells promote excessive fat production during cell division by manipulating the cell's energy status and stress response. This aberrant process is triggered by lifestyle factors that increase oxidative stress—such as poor diet and lack of exercise—which activate a self-amplifying cycle where CB1 receptor activation begets more CB1 receptor upregulation. The consequence is sustained fat synthesis that depletes cellular energy (ATP), triggering increased hunger and food intake, creating a vicious cycle that perpetuates obesity.

These findings have important implications for cannabis users, particularly those consuming high-THC products that strongly activate CB1 receptors. The research suggests that regular CB1 receptor stimulation in the liver may contribute to weight gain through mechanisms beyond simple appetite stimulation, potentially affecting metabolic health at a deeper cellular level. This work also validates the strategy of developing peripherally-restricted drugs that target cannabinoid receptors in specific organs rather than throughout the brain and body, potentially opening new therapeutic avenues for obesity treatment without psychiatric side effects."

📄 Original Abstract

Although an attractive approach for treating obesity-related pathologies, the development of peripherally restricted cannabinoid 1 receptor inhibitors has thus far failed to deliver drugs with clinically validated efficacy and safety margins over central nervous system (CNS)-related side effects. Challenges and frequently occurring misleading assumptions with this strategy are discussed. However, the recently reported peripherally restricted hepatotropic cannabinoid 1 receptor inverse agonist TM38837 is noteworthy due to the substantial weight loss efficacy in DIO rodents coupled with minimal CNS exposure, which suggests that such a chemotype may have clinical utility. Furthermore, hepatic cannabinoid 1 receptor upregulation is implicated as a major driver of the obese phenotype in rodents, which opposes current theories based upon experiments with genetically modified mice. Accordingly, a novel hypothesis is proposed, which implicates cannabinoid 1 receptor upregulation as a mediator of cell cycle progression, which drives lipid synthesis during the mitosis phase. The upregulation is initiated by increasing redox state and amplified by a feed-forward effect whereby cannabinoid 1 receptor activation induces cannabinoid 1 receptor upregulation by increasing expression of pro-oxidant enzymes. This mechanism is activated prematurely in the cell cycle by lifestyle factors, which are known to cause oxidative stress in hepatocytes and are associated with the development of obesity. The consequence of such aberrant cannabinoid 1 receptor upregulation is sustained lipogenesis, leading to reduced cellular ATP levels, which drive increased food intake and contribute to other pathologies.